Please login to the form below
Acquisition
This page shows the latest Acquisition news and features for those working in and with pharma, biotech and healthcare.
GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours
GSK gained dostarlimab from its $5.1bn acquisition of cancer specialist Tesaro, as well as PARP inhibitor Zejula (niraparib), which is approved across a number of indications including ovarian, fallopian tube
Latest news
-
Sanofi gains access to antibody tech with Kymab acquisition
The acquisition will also give Sanofi access to new antibody technologies and research capabilities, the company said in a statement. ... The Kymab acquisition is the first acquisition agreed by Sanofi in 2021, following a string of deals made throughout
-
Servier to acquire Agios’ oncology business in $1.8bn deal
area. “The strategic acquisition of Agios’ oncology business, including its precision medicine portfolio and pipeline, is aligned with our ambition to become a recognised player in oncology and further supports our ... Aside from strengthening its
-
Lilly picks up gene therapy programme in $1bn Prevail Therapeutics acquisition deal
For Lilly, the acquisition will extend its focus into developing gene therapies, establishing an in-house gene therapy programme ‘anchored’ by Prevail’s current portfolio and AAV-based technology. ... We look forward to completing the proposed
-
AstraZeneca to acquire Alexion for $39bn
The acquisition is one of the largest deals announced this year and is also AZ’s largest corporate acquisition ever, according to Reuters. ... This acquisition allows us to enhance our presence in immunology,” said Pascal Soriot, chief executive
-
Boehringer spends €1.18bn to acquire NBE-Therapeutics
The acquisition is expected to close, subject to customary closing conditions, during the first quarter of 2021. ... This acquisition is a further example of Boehringer Ingelheim’s long-term strategy to enhance our position as an innovator of novel
More from news
Approximately 198 fully matching, plus 1,229 partially matching documents found.
Latest Intelligence
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
the pipeline, the use of technology in medicine is expected to grow and so are the associated deals, mergers and acquisitions. ... They also can help identify collaboration opportunities including partnerships, licensing deals and merger or acquisition
-
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
Another example is Biogen’s $800m acquisition of Nightstar’s late-stage gene therapy assets for retinal disease – NSR-REP1 and NSR-RPGR.
-
Rebranding in an evolving world
It goes without saying that partnerships are a fundamental part of that portfolio expansion, which is why another key area of investment has been in mergers and acquisitions. ... We’ve made monumental strides in increasing our European presence through
-
Switzerland: a life sciences hub
A playing field for acquisitions. One of the world’s leading biotech hubs, Switzerland provides over 50, 000 jobs in the sector and, together with the pharmaceutical and chemical industries, contributes ... And yet the acquisition flow demonstrates
-
AI: the smart money is on the smart thinking
Recognising this, big pharma firms are already looking to consolidate with AI solutions, if not through acquisitions, then through partnerships. ... Indeed, this has been evidenced recently by Thermo Fisher’s acquisition of Qiagen in May for $11.5bn.
More from intelligence
Approximately 74 fully matching, plus 93 partially matching documents found.
Latest appointments
-
New hires at FibroGen, Saniona and Turbine
In that role, Barge oversaw the company’s acquisition of Kudos, which yielded the drug Lynparza (olaparib).
-
New hires at Bristol-Myers Squibb, Acceleron and FerGene
Metcalfe joins BMS from CVS Health, where she led communications following the company’s acquisition of Aetna, where she was chief communication officer.
-
New hires at Abbott, Kite and Arrakis Therapeutics
Jude Medical – Abbott’s largest acquisition. He also led Abbott’s Diabetes Care business and the launch of the FreeStyle Libre. ... Most recently, Bosley served as the chief executive officer of Editas Medicine, and previously worked as CEO of
-
New hires at Bayer, Eisai and Accord Healthcare
Marianne De Backer is a recognised business leader with an impressive track record spanning over two decades in research and commercial, as well as licensing, mergers and acquisitions,” said Stefan Oelrich,
-
Lucid Group announces new hires at its creative and digital agency Bluedog
The move was Lucid Group’s first major acquisition, and came as the group celebrated its 12-year anniversary.
More from appointments
Approximately 0 fully matching, plus 119 partially matching documents found.
Latest from PMHub
-
Lucid Group Evolve and Simplify its Brand Architecture
The first acquisition, in Feb 2019, focussed on bringing in new digital and creative skills with the acquisition of Bluedog. ... These acquisitions increased the number of companies sitting under Lucid Group from four, to six: Vivid, Leading Edge, Lucid
-
Envision Pharma Group acquires Two Labs to advance its position as a global strategic partner to pharma and create a unique and unrivaled launch excellence offering
Envision’s acquisition of Two Labs follows the recent announcement of GHO Capital’s increased investment in the company and the backing of management for its continued global expansion. ... A number of strategic acquisitions in medical strategy,
-
GHO Capital and management acquire Ardian majority stake in Envision Pharma Group to accelerate continued growth
Over the last 19 years Envision has enjoyed outstanding year-on-year organic growth, with expansion supplemented via a number of key strategic acquisitions in medical strategy, Health Economics and Market ... growth, adding new service lines via
-
Lucid Group expand its UK office footprint in Macclesfield
The HealthCare21 team have just celebrated its first year anniversary following its acquisition by Lucid Group in September 2019.
-
Virtual Engagement At Porterhouse: Reflections on the past few months
adapt to the virtual environment as a matter of necessity; this has instigated rapid acquisition of a skill set that can be used during the COVID-19 pandemic and beyond.
More from PMHub
Approximately 8 fully matching, plus 73 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Medical Editor
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Healthcare Lead Copywriter
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
-
Healthcare Account Director
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
- Sinovac’s COVID-19 vaccine appears safe in older adults
- Celltrion’s investigational mAb cuts COVID-19 recovery time
- New study identifies drugs that are safe to use in COVID-19 treatment
- UK pharmacies to begin administering COVID-19 vaccinations
- PHE study finds people who have had COVID-19 can still transmit the virus
- CureVac set to begin phase 3 COVID-19 vaccine study in healthcare workers
- EU proposes vaccine-sharing mechanism with low-income countries
- Valneva set to begin commercial manufacturing of COVID-19 vaccine within days
- WHO’s director-general deems vaccine nationalism a “catastrophic moral failure”
- Lilly partners with Merus on development of bispecific antibodies for cancer
- Medical research charities need our help – support is needed to continue funding life-saving research and improving lives
- Research Partnership appoints Hannah Osborn to MedTech director role
PMHub
Pegasus
Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...
Latest intelligence
- Sourcing R&D innovation: why pharma companies need to evolve their business models
- Recent years have seen a significant shift in drug development to specialty areas...
- 2020 - a year to remember or forget?
- 2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
- The search for effective drug treatments for COVID-19
- PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...
Quick links
Infographics
